Dermatology Times June 2026 Recap

Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.

New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.

The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.

Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.

Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.

Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.

New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.

SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.